Sanofi Aventis Groupe

PARIS - - 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R) Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir.

PARIS - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone - 400mg Tablets).

NEW ORLEANS - What Live Webcast: Delivering real patient benefit: Update on new clinical excellence & future company vision Live from the American Diabetes Association 69th Scientific Session When Sunday, June 7th, 2009 10:30am - 11:30am CDT (Central Daylight Time) New Orleans, Louisiana, USA 17:30pm - 18:30pm CEST (Central European Summer Time) Paris, France How to register www.videonewswire.com/event.asp?id=59340 Password: sa2009ADA Highlights This webcast event will feature breaking news from real-life and clinical studies on progress in glycemic control, medication safety, cost-effectiveness, patient well-being and satisfaction.